SWKH

SWK Holdings Corporation

16.72 USD

Last updated Dec 10, 23:10 UTC

Yesterday HIGH

$17.23

Yesterday LOW

$16.5

52w HIGH

$19.99

52w LOW

$15.26

EPS

0.38

PE

44.00

Next Earnings

Apr 1, 2024

Overview News Government Trades

SWK Holdings Corporation stock is up 3.53% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 48% of the previous 24 December’s closed higher than November.

SWK Holdings Corporation provides customized financing solutions to a range of life science companies. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endocrine disease. The company was founded in 1996 and is headquartered in Dallas, Texas.

Stock Exchange

OTC

Sector

Finance, Insurance, And Real Estate

Industry

Banking

Headquarters

-

Website

swkhold.com

Lisa Levin

Mon Apr 3, 2023

Tesla, McDonald's And 3 Stocks To Watch Heading Into Monday

With US futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Lisa Levin

Mon Apr 3, 2023

Fear & Greed Index Moves To 'Neutral' Zone As US Stocks Record Gains

The CNN Money Fear and Greed index moved to the "Neutral" zone on Friday. US stocks closed higher on Friday, also recording gains for the quarter after the Federal Reserve’s preferred gauge of inflation showed a cooler-than-expected rise in prices.
Bill Haddad

Tue Jan 3, 2023

SWK Holdings Names Jody Staggs Chief Executive Officer
Benzinga Insights

Fri Dec 16, 2022

SWK Holdings Earnings Perspective: Return On Capital Employed
Benzinga Newsdesk

Wed Nov 9, 2022

SWK Holdings Q3 EPS $0.51 Up From $0.33 YoY, Sales $13.61M Up From $9.56M YoY

SWK Holdings (NASDAQ:SWKH) reported quarterly earnings of $0.51 per share. This is a 54.55 percent increase over earnings of $0.33 per share from the same period last year. The company reported $13.61 million in sales
Benzinga Newsdesk

Wed Oct 26, 2022

Enteris BioPharma Presents Study Of Ovarest Demonstrating Oral Delivery Comparable To Or Exceeding Injectable Leuprolide

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (NASDAQ:SWKH), announced
Benzinga Newsdesk

Mon Oct 10, 2022

SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5M Milestone Payment from Cara Therapeutics

Milestone payment highlights ongoing clinical progress of Oral KORSUVA™ DALLAS, Oct. 10 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH), a life sciences focused specialty finance
Benzinga Newsdesk

Mon Oct 3, 2022

SWK Holdings Enhances Executive Management Team And Expands Underwriting Team; Yvette Heinrichson Promoted To CFO Replaces Charles Jacobson

Yvette Heinrichson promoted to Chief Financial Officer John David Tamas promoted to Director of Underwriting DALLAS, Oct. 3, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH)
Benzinga Insights

Wed Sep 7, 2022

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 297 companies achieved new lows for the year.
Benzinga Newsdesk

Thu Sep 1, 2022

SWK Holdings Announces Jody Staggs Has Been Appoints President And Interim CEO